| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth |
| 21 Sep 2026 |
8-K: Financial Statements and Exhibits
Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth |
| 11 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
This Amendment No. 1 (this “Amendment”) to the AnaptysBio, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”) was approved and adopted by the Board of Directors (the “Board”) of AnaptysBio, Inc. (the “Company”) on the date... |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, on November 20, 2025, AnaptysBio, Inc. (the “Company”) filed a Verified Complaint in Delaware Court of Chancery (the “Court”), requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached t... |
| 22 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to ... |
| 29 May 2026 |
8-K: Regulation FD Disclosure
AnaptysBio, Inc. (the “Company”) has filed Form 8937 with the IRS and will also post Form 8937 information under the “Investors” section of its website at www.anaptysbio.com. The Form 8937 provides information about the dividend received... |
| 21 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June 30. The Company’s next fiscal year will begin on July 1, 2026. The Company plans to f... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business |
| 11 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026. |
| 20 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
NO AGREEMENT, ORAL OR WRITTEN, REGARDING OR RELATING TO ANY OF THE MATTERS COVERED BY THIS DRAFT AGREEMENT HAS BEEN ENTERED INTO BETWEEN THE PARTIES. THIS DOCUMENT, IN ITS PRESENT FORM OR AS IT MAY BE HEREAFTER REVISED BY ANY PARTY, WILL... |
| 27 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 26, 2026, by and among First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”),... |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April |
| 09 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the t... |
| 26 Nov 2025 |
8-K: Regulation FD Disclosure
2 3. The dispute relates to the 2014 Collaboration and Exclusive License Agreement (the “Collaboration Agreement” (Ex. 1)1) between AnaptysBio and Tesaro, which gave Tesaro rights to AnaptysBio’s promising PD-1 antagonist (“PD-1”), dosta... |
| 21 Nov 2025 |
8-K: Other Events
SAN DIEGO, Nov. 21, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repu... |
| 21 Nov 2025 |
8-K: Other Events
On November 20, 2025, AnaptysBio, Inc. (AnaptysBio) filed a Verified Complaint (the “Complaint”) in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. has materially breached the parties’ Collaboration and Exclusiv... |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the t... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, Nov. 4, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, ... |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the t... |
| 29 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Sept. 29, 2025 Strategic Separation to Maximize Shareholder Value |
Loading...